Lyell Immunopharma Reports Board and Executive Changes
Ticker: LYEL · Form: 8-K · Filed: Nov 26, 2024 · CIK: 1806952
| Field | Detail |
|---|---|
| Company | Lyell Immunopharma, Inc. (LYEL) |
| Form Type | 8-K |
| Filed Date | Nov 26, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: LYEL
TL;DR
Lyell Immunopharma (LYEL) filed an 8-K detailing board and exec comp changes. No specific names or $ yet.
AI Summary
Lyell Immunopharma, Inc. announced on November 22, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its key executives. The filing does not specify the exact individuals involved or the financial details of the compensation changes.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect the company's future direction and performance.
Key Players & Entities
- Lyell Immunopharma, Inc. (company) — Registrant
- November 22, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 201 Haskins Way, South San Francisco, California 94080 (address) — Principal Executive Offices
FAQ
What specific items are being reported under the 8-K filing?
The filing reports on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
When was the earliest event reported in this filing?
The earliest event reported was on November 22, 2024.
What is the principal executive office address for Lyell Immunopharma, Inc.?
The principal executive office is located at 201 Haskins Way, South San Francisco, California 94080.
What is the SIC code for Lyell Immunopharma, Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 416 words · 2 min read · ~1 pages · Grade level 12.2 · Accepted 2024-11-26 16:05:53
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LYEL The Nasdaq
Filing Documents
- d848587d8k.htm (8-K) — 22KB
- 0001193125-24-266101.txt ( ) — 137KB
- lyel-20241122.xsd (EX-101.SCH) — 3KB
- lyel-20241122_lab.xml (EX-101.LAB) — 17KB
- lyel-20241122_pre.xml (EX-101.PRE) — 11KB
- d848587d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lyell Immunopharma, Inc. Date: November 26, 2024 By: /s/ Matthew Lang Matthew Lang Chief Business Officer